Press release·08/14/2026 23:10:49

Overview

Callan JMB is a vertically integrated logistics and fulfillment company that provides thermal management solutions to the life sciences industry. The company utilizes proprietary packaging, information technology, and specialized cold chain logistics expertise to revolutionize the supply chain and ensure the safety, effectiveness, and potency of every product handled. Callan JMB aims to be recognized as the premier provider of logistics and fulfillment services in its industry.

Financial Performance

Callan JMB’s financial performance for the three and six months ended June 30, 2026, showed mixed results compared to the same periods in 2025.

Revenue for the three-month period decreased by 17% to $1,376,326, while revenue for the six-month period decreased by 20% to $2,482,468. This decline was primarily due to a decrease in demand for the company’s emergency preparedness services by certain states and local governments.

Despite the revenue decline, Callan JMB was able to improve its gross profit margin. Gross profit for the three-month period increased by 18% to $757,946, while gross profit for the six-month period decreased by 6% to $1,185,180. The improvement in the three-month period was driven by a 40% decrease in cost of revenue, which was attributed to lower shippers and components costs, direct labor costs, and other expenses.

On the other hand, the company’s selling, general, and administrative (SG&A) expenses increased during the periods. SG&A expenses for the three-month period increased by 3% to $2,104,592, and for the six-month period, the increase was 8% to $4,233,015. The primary drivers of the SG&A increase were higher legal expenses, salaries and benefits, accounting fees, rent, and other operating costs.

The combination of lower revenue and higher SG&A expenses resulted in Callan JMB reporting a net loss of $1,231,923 for the three-month period and $4,446,977 for the six-month period. These losses represent a 12% and 68% improvement, respectively, compared to the same periods in 2025.

Liquidity and Capital Resources

Callan JMB’s liquidity and capital resources position raised substantial doubt about the company’s ability to continue as a going concern. As of June 30, 2026, the company had $860,273 in cash and cash equivalents, an accumulated deficit of $14,706,991, and negative cash flow from operating activities of $2,075,943 for the six-month period.

The company has been funding its operations through a combination of cash on hand, cash flows from operations, and funding from various sources, including the CEO. However, the company’s recurring losses and inability to generate sufficient cash flows from operations to fund its activities have raised concerns about its ability to continue as a going concern.

Callan JMB is actively exploring additional sources of capital, including equity and debt financings, to address its liquidity and capital needs. However, the availability and terms of future financing are subject to market conditions, investor demand, and the company’s operating performance, and there can be no assurance that additional capital will be available when needed or on acceptable terms.

Regulatory Compliance

Callan JMB is also facing regulatory challenges related to its listing on the Nasdaq Stock Market. On April 7, 2026, the company received a notice from Nasdaq that it was not in compliance with the minimum $2.5 million stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company has submitted a compliance plan to Nasdaq and is working to regain compliance, but there is no assurance that it will be able to do so within the time frame granted by Nasdaq.

Additionally, on June 29, 2026, the company received a notice from Nasdaq indicating that it was not in compliance with the minimum $1.00 closing bid price requirement. The company has until December 28, 2026, to regain compliance with the minimum bid price requirement. The company is actively monitoring its compliance with Nasdaq’s continued listing requirements and evaluating alternatives to regain and maintain compliance, but there is no guarantee that it will be successful.

Strengths and Weaknesses

Strengths:

• Callan JMB’s core competencies in proprietary packaging, information technology, and specialized cold chain logistics expertise provide a competitive advantage in the life sciences industry.
• The company’s comprehensive and customized solutions are seen as disruptive to traditional “dry ice and liquid nitrogen” logistics approaches, offering reliable and economic alternatives.
• Callan JMB’s ability to monitor, record, and archive crucial information for each shipment can be valuable for scientific and regulatory purposes.

Weaknesses:

• The company’s financial performance has been weak, with declining revenue, recurring losses, and negative cash flow from operations.
• Callan JMB’s liquidity and capital resources position raise substantial doubt about its ability to continue as a going concern, as it relies on funding from the CEO and other sources to sustain its operations.
• The company’s regulatory compliance issues with Nasdaq’s listing requirements pose a significant risk to its continued operations and access to capital markets.

Outlook and Future Prospects

Callan JMB’s future prospects are uncertain due to the company’s financial and regulatory challenges. The continued decline in revenue and the inability to generate sufficient cash flows from operations to fund its activities are significant concerns. The company’s efforts to secure additional financing and regain compliance with Nasdaq’s listing requirements will be crucial in determining its long-term viability.

If Callan JMB is unable to address its liquidity and capital needs, it may face the risk of insolvency or delisting from the Nasdaq Stock Market, which could further undermine its financial position and ability to operate. The company’s management will need to develop and execute a comprehensive turnaround strategy to stabilize the business, improve financial performance, and regain the confidence of investors and regulatory authorities.

In the short term, Callan JMB’s focus should be on addressing its immediate liquidity and regulatory compliance issues. This may involve securing additional financing, implementing cost-cutting measures, and working closely with Nasdaq to regain compliance with the listing requirements. Failure to do so could result in the company’s delisting and further financial distress.

In the long term, Callan JMB will need to re-evaluate its business strategy, operational efficiency, and competitive positioning to ensure it can capitalize on the growth opportunities in the life sciences logistics market. This may require the company to make strategic investments, diversify its customer base, and explore new revenue streams that leverage its core competencies.

Overall, Callan JMB faces significant challenges in the near-term, and its long-term success will depend on the company’s ability to address its financial and regulatory issues, while also developing a sustainable and competitive business model that can generate consistent profitability and cash flows.